Filing Flows › Surrozen (SRZN) › Recalls, complaints & regulation
Surrozen (SRZN): clinical trials
Surrozen (SRZN) beyond its filings: 1 active clinical trial.
Surrozen's latest quarter
Surrozen, Q2 2026: revenue $5.0M (+409% year over year), operating margin -207.4%, net earnings $50.2M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Surrozen have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.